STOCK PLAN

3 Months Ended

Mar. 31, 2026

NOTE E - STOCK PLAN

The Company has reserved 10,000,000 shares of common stock for issuance to employees or consultants from the RetinalGenix Technologies Inc. 2017 Equity Incentive Plan (the “Plan”). The Company may grant stock options, restricted stock or other types of equity incentive instruments under the Plan.

The Company recognized $0 and $23,457 of stock-based compensation expense during the three months ended March 31, 2026 and 2025, respectively, related to stock options which is included in the accompanying condensed consolidated statements of operations. As of March 31, 2026, there was approximately no unrecognized compensation expense related to non-vested stock options granted under the Plan.

At March 31, 2026, there were 7,290,000 shares available to be issued under the Plan. The following table summarizes stock option activity of the Plan through March 31, 2026:

SCHEDULE OF STOCK OPTION ACTIVITY

	Options Issued			Weighted-Average Exercise Price

Options outstanding – December 31, 2024 (audited)		2,415,000		$	1.23
Granted		-			-
Canceled		-			-
Forfeited		(1,635,000	)		1.00
Exercised		-
Options outstanding – December 31, 2025 (audited)		780,000		$	1.72
Granted		-			-
Canceled		-			-
Forfeited		-			-
Exercised		-			-
Options outstanding – March 31, 2026		780,000		$	1.72

Additional information regarding the exercisable options and average remaining contractual life of the options outstanding as of March 31, 2026 is as follows:

Exercise Price		Number Outstanding		Weighted Average Remaining Contractual Life		Number Exercisable at March 31, 2026
$	1.00		500,000		5.7 Years		500,000
	3.00		280,000		1.8 Years		280,000
			780,000				780,000

RetinalGenix Technologies Inc. 10-Q